Non-alcoholic fatty liver disease (NAFLD) diagnosis and management-differentiating the essential from the ancillary and the present from the future.
作者信息
Lonardo Amedeo, Lugari Simonetta, Nascimbeni Fabio
机构信息
Operating Unit Internal Medicine, AOU, Ospedale Civile di Baggiovara, Modena, Italy.
University of Modena and Reggio Emilia, Modena, Italy.
出版信息
Hepatobiliary Surg Nutr. 2020 Jun;9(3):374-378. doi: 10.21037/hbsn.2019.11.12.
Abstract
摘要
相似文献
1
Non-alcoholic fatty liver disease (NAFLD) diagnosis and management-differentiating the essential from the ancillary and the present from the future.非酒精性脂肪性肝病（NAFLD）的诊断与管理——区分基本要素与辅助要素，明晰现状与未来。
Hepatobiliary Surg Nutr. 2020 Jun;9(3):374-378. doi: 10.21037/hbsn.2019.11.12.
2
Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.评估中国代谢综合征与肝活检证实的非酒精性脂肪性肝炎之间的关系：一项多中心横断面研究设计
Adv Ther. 2016 Nov;33(11):2069-2081. doi: 10.1007/s12325-016-0416-4. Epub 2016 Oct 14.
3
Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.酒精性肝病（ALD）/非酒精性脂肪性肝病（NAFLD）指数联合γ-谷氨酰转移酶在鉴别ALD和NAFLD中的诊断价值。
Korean J Intern Med. 2016 May;31(3):479-87. doi: 10.3904/kjim.2015.253. Epub 2016 Mar 30.
4
From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.从糖到肝脂肪和公共健康：系统生物学驱动的非酒精性脂肪性肝病发病机制研究。
Proc Nutr Soc. 2019 Aug;78(3):290-304. doi: 10.1017/S0029665119000570. Epub 2019 Mar 29.
5
Characteristics and diagnosis of NAFLD/NASH.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的特征和诊断。
J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:64-70. doi: 10.1111/jgh.12271.
6
Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.非酒精性脂肪性肝病中纤维化的无创诊断
J Clin Exp Hepatol. 2012 Jun;2(2):145-55. doi: 10.1016/S0973-6883(12)60103-0. Epub 2012 Jul 21.
7
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.系统评价：成人非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学和自然史。
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30.
8
Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future.膳食补充剂与儿童非酒精性脂肪性肝病：现状与未来。
World J Hepatol. 2015 Nov 8;7(25):2597-602. doi: 10.4254/wjh.v7.i25.2597.
9
Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).用于诊断非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）的单一非侵入性模型。
J Gastroenterol Hepatol. 2014 Dec;29(12):2006-13. doi: 10.1111/jgh.12665.
10
Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study.非酒精性脂肪性肝病与亚临床冠状动脉粥样硬化的相关性：一项观察性队列研究。
J Hepatol. 2018 May;68(5):1018-1024. doi: 10.1016/j.jhep.2017.12.012. Epub 2017 Dec 20.
引用本文的文献
1
Artificial Intelligence in NAFLD: Will Liver Biopsy Still Be Necessary in the Future?非酒精性脂肪性肝病中的人工智能：未来肝脏活检是否仍有必要？
Healthcare (Basel). 2022 Dec 30;11(1):117. doi: 10.3390/healthcare11010117.
2
Cholesterol-induced leucine aminopeptidase 3 (LAP3) upregulation inhibits cell autophagy in pathogenesis of NAFLD.胆固醇诱导亮氨酸氨肽酶 3（LAP3）上调抑制 NAFLD 发病机制中的细胞自噬。
Aging (Albany NY). 2022 Apr 11;14(7):3259-3275. doi: 10.18632/aging.204011.
3
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management.精准医学方法在非酒精性脂肪性肝病诊断和管理中的应用展望。
Adv Ther. 2021 May;38(5):2130-2158. doi: 10.1007/s12325-021-01690-1. Epub 2021 Apr 7.
4
Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.非酒精性脂肪性肝病（NAFLD）作为精神疾病被忽视的代谢伴发疾病：共同途径和未来方法。
BMC Med. 2020 Oct 1;18(1):261. doi: 10.1186/s12916-020-01713-8.
本文引用的文献
1
A critical appraisal of the use of ultrasound in hepatic steatosis.超声在肝脂肪变性中的应用评价。
Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):667-681. doi: 10.1080/17474124.2019.1621164. Epub 2019 May 29.
2
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.非酒精性脂肪性肝病的性别差异：现状与研究空白的识别。
Hepatology. 2019 Oct;70(4):1457-1469. doi: 10.1002/hep.30626. Epub 2019 Sep 23.
3
Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.用反义寡核苷酸沉默 Pnpla3 可改善 Pnpla3 I148M 敲入小鼠的非酒精性脂肪性肝炎和肝纤维化。
Mol Metab. 2019 Apr;22:49-61. doi: 10.1016/j.molmet.2019.01.013. Epub 2019 Feb 5.
4
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者肝脏疾病的无创评估。
Gastroenterology. 2019 Apr;156(5):1264-1281.e4. doi: 10.1053/j.gastro.2018.12.036. Epub 2019 Jan 18.
5
New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease.非酒精性脂肪性肝病遗传易感性的新见解及新治疗靶点
Hepatobiliary Surg Nutr. 2018 Oct;7(5):372-381. doi: 10.21037/hbsn.2018.08.05.
6
A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis.一种基因评分与非酒精性脂肪性肝炎患者对吡格列酮的反应相关。
Front Pharmacol. 2018 Jul 17;9:752. doi: 10.3389/fphar.2018.00752. eCollection 2018.
7
Current and future pharmacological therapies for NAFLD/NASH.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的当前和未来药理学治疗方法。
J Gastroenterol. 2018 Mar;53(3):362-376. doi: 10.1007/s00535-017-1415-1. Epub 2017 Dec 16.
8
Clinical relevance of liver histopathology and different histological classifications of NASH in adults.成人非酒精性脂肪性肝炎的肝脏组织病理学和不同组织学分类的临床相关性。
Expert Rev Gastroenterol Hepatol. 2018 Apr;12(4):351-367. doi: 10.1080/17474124.2018.1415756. Epub 2017 Dec 26.
9
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
10
Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.2017年亚太地区非酒精性脂肪性肝病工作小组指南 - 第1部分：定义、危险因素及评估
J Gastroenterol Hepatol. 2018 Jan;33(1):70-85. doi: 10.1111/jgh.13857.
Zotero 插件